In March 2018, MAPS raised over $265,000 in new donations and pledges from 451 supporters.
Starting on January 10, MAPS has been raising funds to be matched by a $4 million matching grant, offered by the Pineapple Fund. MAPS completed the matching grant on March 7, raising $8 million for our FDA Phase 3 clinical trials of MDMA-assisted psychotherapy for the treatment of PTSD.
With these gifts, MAPS has now raised $26.2 million of the $26.7 million needed for our upcoming Phase 3 clinical trials. MAPS now needs an additional $500,000 to complete funding for the final stage of research needed to make MDMA-assisted psychotherapy a legal prescription treatment for PTSD in the U.S. MAPS is currently seeking an additional $5 million for European Medicines Agency (EMA) trials to supplement the data gathered for the FDA. MAPS has raised over $400,000 toward our European studies, but we still need $4.6 million.
We extend a special thanks to those who so generously supported MAPS last month:
- Grant Leonard ($1,100)
MDMA/PTSD Phase 3 Studies (U.S.):
- Fundamental ($25,000)
- Karl Richard ($2,500)
- Elliod Godzich ($1,200)
- Kevin Reed ($1,000)
- Shawna & Steve Huser ($1,000)
MDMA/PTSD Phase 3 Studies (Europe):
- Christian Halper ($200,000)
- Ronald A. Mis ($10,000)
MAPS relies on the generosity of individual donors to achieve our mission. Psychedelic science is again being conducted under federal guidelines, but no funding for psychedelic psychotherapy research is yet available from governments or major non-family foundations.
Help us reach our goal to make MDMA a medicine by 2021 by establishing a monthly gift of $10 or more. maps.org/donate